SEC Comment Letter for Altimmune, Inc. (ALT) (CIK 0001326190) (ALT) — Aug 8, 2018
Altimmune, Inc. (ALT) (CIK 0001326190)
Date: Aug. 8, 2018 · CIK: 0001326190 · Accession: 0000000000-18-024591
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226441
Letter
August 8, 2018 William Enright President and Chief Executive Officer Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 Re:Altimmune, Inc. Registration Statement on Form S-1 Filed July 30, 2018 File No. 333-226441 Dear Mr. Enright: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Irene Paik at 202-551-6553 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Stuart Bressman, Esq. - Proskauer Rose LLP
Show Raw Text
August 8, 2018
William Enright
President and Chief Executive Officer
Altimmune, Inc.
910 Clopper Road, Suite 201S
Gaithersburg, Maryland 20878
Re:Altimmune, Inc.
Registration Statement on Form S-1
Filed July 30, 2018
File No. 333-226441
Dear Mr. Enright:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Irene Paik at 202-551-6553 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Stuart Bressman, Esq. - Proskauer Rose LLP